Journal Mobile Options
Table of Contents
Vol. 32, No. 4, 2009
Issue release date: April 2009
Neuroepidemiology 2009;32:257–262
(DOI:10.1159/000201564)

Association of Infectious Mononucleosis with Multiple Sclerosis

A Population-Based Study

Ramagopalan S.V. · Valdar W. · Dyment D.A. · DeLuca G.C. · Yee I.M. · Giovannoni G. · Ebers G.C. · Sadovnick A.D.
aWellcome Trust Centre for Human Genetics, and bDepartment of Clinical Neurology, University of Oxford, Oxford, UK; cDepartment of Medical Genetics and dFaculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, B.C., Canada; eInstitute of Cell and Molecular Science, Queen Mary University, and the Department of Neurology, Barts and The London NHS Trust, The Royal London Hospital, London, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Genetic and environmental factors have important roles in multiple sclerosis (MS) susceptibility. Several studies have attempted to correlate exposure to viral illness with the subsequent development of MS. Here in a population-based Canadian cohort, we investigate the relationship between prior clinical infection or vaccination and the risk of MS. Methods: Using the longitudinal Canadian database, 14,362 MS index cases and 7,671 spouse controls were asked about history of measles, mumps, rubella, varicella and infectious mononucleosis as well as details about vaccination with measles, mumps, rubella, hepatitis B and influenza vaccines. Comparisons were made between cases and spouse controls. Results: Spouse controls and stratification by sex appear to correct for ascertainment bias because with a single exception we found no significant differences between cases and controls for all viral exposures and vaccinations. However, 699 cases and 165 controls reported a history of infectious mononucleosis (p < 0.001, corrected odds ratio 2.06, 95% confidence interval 1.71–2.48). Females were more aware of disease history than males (p < 0.001). Conclusions: The data further confirms a reporting distortion between males and females. Historically reported measles, mumps, rubella, varicella and vaccination for hepatitis B, influenza, measles, mumps and rubella are not associated with increased risk of MS later in life. A clinical history of infectious mononucleosis is conspicuously associated with increased MS susceptibility. These findings support studies implicating Epstein-Barr virus in MS disease susceptibility, but a co-association between MS susceptibility and clinically apparent infectious mononucleosis cannot be excluded.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med 2000;343:938–952.
  2. Ebers GC: Environmental factors and multiple sclerosis. Lancet Neurol 2008;7:268–277.
  3. Ebers GC, Sadovnick AD, Risch NJ: A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995;377:150–151.
  4. Pugliatti M, Sotgiu S, Rosati G: The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182–191.
  5. Dean G, Elian M: Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:565–568.
  6. Kurtzke JF: Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993;6:382–427.
  7. Kurtzke JF, Hyllested K: Multiple sclerosis: an epidemic disease in the Faeroes. Trans Am Neurol Assoc 1975;100:213–215.
  8. Sibley WA, Foley JM: Infection and immunization in multiple sclerosis. Ann NY Acad Sci 1965;122:457–466.
  9. Millar JH, Fraser KB, Haire M, Connolly JH, Shirodaria PV, Hadden DS: Immunoglobulin M specific for measles and mumps in multiple sclerosis. BMJ 1971;ii:378–380.

    External Resources

  10. Horikawa Y, Tsubaki T, Nakajima M: Rubella antibody in multiple sclerosis. Lancet 1973;1:996–997.
  11. Ross CA, Lenman JA, Rutter C: Infective agents and multiple sclerosis. BMJ 1965;i: 226–229.

    External Resources

  12. Sumaya CV, Myers LW, Ellison GW: Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol 1980;37:94–96.
  13. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol 2007;61:288–299.
  14. Paty DW, Ebers GC: Multiple Sclerosis. Philadelphia, Davis, 1998.
  15. Pekmezovic T, Jarebinski M, Drulovic J: Childhood infections as risk factors for multiple sclerosis: Belgrade case-control study. Neuroepidemiology 2004;23:285–288.
  16. Tarrats R, Ordonez G, Rios C, Sotelo J: Varicella, ephemeral breastfeeding and eczema as risk factors for multiple sclerosis in Mexicans. Acta Neurol Scand 2002;105:88–94.
  17. Bager P, Nielsen NM, Bihrmann K, Frisch M, Hjalgrim H, Wohlfart J, Koch-Henriksen N, Melbye M, Westergaard T: Childhood infections and risk of multiple sclerosis. Brain 2004;127:2491–2497.
  18. Lindberg C, Andersen O, Vahlne A, Dalton M, Runmarker B: Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 1991;10:62–65.
  19. Nielsen TR, Rostgaard K, Nielsen NM, Koch-Henriksen N, Haahr S, Sorensen PS, Hjalgrim H: Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007;64:72–75.
  20. Marrie RA, Wolfson C, Sturkenboom MC, Gout O, Heinzlef O, Roullet E, Abenhaim L: Multiple sclerosis and antecedent infections: a case-control study. Neurology 2000;54:2307–2310.
  21. Zaadstra B, Chorus A, van Buuren S, Kalsbeek H, van Noort J: Selective association of multiple sclerosis with infectious mononucleosis. Mult Scler 2008;14:307–313.
  22. de la Monte SM, Ropper AH, Dickersin GR, Harris NL, Ferry JA, Richardson EP Jr: Relapsing central and peripheral demyelinating diseases: unusual pathologic features. Arch Neurol 1986;43:626–629.
  23. Herroelen L, de Keyser J, Ebinger G: Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991;338:1174–1175.
  24. Stevenson VL, Acheson JF, Ball J, Plant GT: Optic neuritis following measles/rubella vaccination in two 13-year-old children. Br J Ophthalmol 1996;80:1110–1111.
  25. Zanoni G, Nguyen TM, Destefani E, Masala L, Nardelli E, Tridente G: Transverse myelitis after vaccination. Eur J Neurol 2002;9:696–697.
  26. Kline LB, Margulies SL, Oh SJ: Optic neuritis and myelitis following rubella vaccination. Arch Neurol 1982;39:443–444.
  27. DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, Mullooly JP, Likosky W, Chen RT: Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003;60:504–509.
  28. Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IM, Sadovnick AD, Ebers GC: Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007;6:604–610.
  29. Sadovnick AD, Risch NJ, Ebers GC: Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and method. Canadian Collaborative Study Group. Can J Neurol Sci 1998;25:216–221.
  30. R-Development-Core-Team: R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2005.
  31. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006;5:932–936.
  32. Robertson NP, O’Riordan JI, Chataway J, Kingsley DP, Miller DH, Clayton D, Compston DA: Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet 1997;349:1587–1590.
  33. Ebers GC, Yee IM, Sadovnick AD, Duquette P: Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann Neurol 2000;48:927–931.
  34. Ebers GC, Sadovnick AD, Dyment DA, Yee IM, Willer CJ, Risch N: Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004;363:1773–1774.
  35. Dyment DA, Yee IM, Ebers GC, Sadovnick AD: Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. J Neurol Neurosurg Psychiatry 2006;77:258–259.
  36. Ascherio A, Munch M: Epstein-Barr virus and multiple sclerosis. Epidemiology 2000;11:220–224.
  37. Sundstrom P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nystrom L, Dillner J, Forsgren L: An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004;62:2277– 2282.
  38. Thacker EL, Mirzaei F, Ascherio A: Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006;59:499–503.
  39. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB: An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019–3026.
  40. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, Hjorth P, Sondergaard L, Svejgaard A, Wucherpfennig K, Stuart DI, Bell JI, Jones EY, Fugger L: A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002;3:940–943.
  41. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F: Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899–2912.
  42. Hernan MA, Zhang SM, Lipworth L, Olek MJ, Ascherio A: Multiple sclerosis and age at infection with common viruses. Epidemiology 2001;12:301–306.
  43. Bachmann S, Kesselring J: Multiple sclerosis and infectious childhood diseases. Neuroepidemiology 1998;17:154–160.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50